Repositioning Candidate Details
| Candidate ID: | R0734 |
| Source ID: | DB05202 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Egaptivon pegol |
| Synonyms: | Egaptivon pegol |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. |
| CAS Number: | 934868-74-3 |
| Molecular Weight: | |
| DrugBank Indication: | Platelet aggregation, thrombosis and acute coronary syndromes |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart. |
| Targets: | von Willebrand factor; Platelet glycoprotein Ib alpha chain |
| Inclusion Criteria: | Target associated |
